Long COVID Immune Profiling

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test, Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Parasympathetic nervous system (PNS) is part of the body's autonomic nervous system(PNS) protects body against inflammation. Study shows that reduced PNS function activity is associated with persistent inflammation. Preliminary data from the studies shows, that post-COVID-19 POTS patients have reduced parasympathetic (PNS) function. Given that the PNS protects against inflammation, this clinical trial aims to prove that post-COVID-19 POTS is caused by reduced PNS activity, which in turn, contributes to persistent inflammation, orthostatic intolerance, and OI symptoms. The study will evaluate immune cell activation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• Subjects will be 18 years or older, men and women.

• History of confirmed COVID-19 infection (positive contact and symptoms, antigen test or PCR).

• POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms.

• Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\>30 bpm) and chronic (\>3 months) pre-syncopal symptoms. Symptoms occurred within 2 months after COVID infection and persistent until enrollment in the study.

Locations
United States
Tennessee
Cyndya Shibao
RECRUITING
Nashville
Contact Information
Primary
Marwa Mohamed, Phd
marwa.mohamed@vumc.org
6159702384
Backup
Cyndya Shibao, MD
cyndya.shibao@vumc.org
615-322-3447
Time Frame
Start Date: 2024-04-24
Estimated Completion Date: 2026-10-31
Participants
Target number of participants: 150
Treatments
Other: Post- COVID 19 POTS patients
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31): In post-COVID-19 POTS (cases).
Other: POTS patients
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: patients with diagnosis of POTS
Other: Post- COVID 19 POTS patients with Controls
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: Controls are :COVID-19 infected without sequelae
Sponsors
Leads: Vanderbilt University Medical Center
Collaborators: American Heart Association

This content was sourced from clinicaltrials.gov